Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
复制标题
万古霉素联合头孢洛林或苯唑西林对抗甲氧西林耐药万古霉素中型金黄色葡萄球菌 (VISA) 和异质 VISA 的新型组合。
DOI：
10.1128/aac.02354-12
复制
发表时间：
2013
影响因子：
4.9
通讯作者：
Rybak,MJ
中科院分区：
文献类型：
--
作者：
Werth,BJ;Vidaillac,C;Murray,KP;Newton,KL;Sakoulas,G;Nonejuie,P;Pogliano,J;Rybak,MJ
We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively. Beta-lactam exposure reduced overall vancomycin-Bodipy (dipyrrometheneboron difluoride [4,4-difluoro-4-bora-3a,4a-diaza-s-indacene] fluorescent dye) binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.
